Among these, IGF2BP2 emerged as the most promising therapeutic target due to its role in maintaining tumor-initiating cell populations across multiple cancer types, including colon cancer and gliomas.95 This evidence concerns the gene IGF2BP2 and malignant colon neoplasm.